4880 Stock Overview
Engages in the regenerative medicine-related businesses in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CellSource Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,493.00 |
| 52 Week High | JP¥2,600.00 |
| 52 Week Low | JP¥1,129.00 |
| Beta | 0.21 |
| 11 Month Change | -1.13% |
| 3 Month Change | 12.26% |
| 1 Year Change | -30.40% |
| 33 Year Change | -72.74% |
| 5 Year Change | n/a |
| Change since IPO | 91.41% |
Recent News & Updates
A Look At The Fair Value Of CellSource Co., Ltd. (TSE:4880)
Aug 13
Shaky Earnings May Not Tell The Whole Story For CellSource (TSE:4880)
Jun 20Shareholder Returns
| 4880 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | 7.6% | 9.6% | 2.9% |
| 1Y | -30.4% | -33.8% | 14.9% |
Return vs Industry: 4880 exceeded the JP Life Sciences industry which returned -35.4% over the past year.
Return vs Market: 4880 underperformed the JP Market which returned 15% over the past year.
Price Volatility
| 4880 volatility | |
|---|---|
| 4880 Average Weekly Movement | 9.1% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in JP Market | 10.1% |
| 10% least volatile stocks in JP Market | 3.4% |
Stable Share Price: 4880 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4880's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 151 | Takashi Sawada | www.cellsource.co.jp |
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients’ adipose tissues, and to prepare platelet-rich plasma from patients’ blood; and offers support services for medical facilities providing regenerative medicine therapy, as well as manufacturing processed cells. It is also involved in the development and sale of Signalift series of anti-aging products, including a serum.
CellSource Co., Ltd. Fundamentals Summary
| 4880 fundamental statistics | |
|---|---|
| Market cap | JP¥29.57b |
| Earnings (TTM) | JP¥812.00m |
| Revenue (TTM) | JP¥4.57b |
36.4x
P/E Ratio6.5x
P/S RatioIs 4880 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4880 income statement (TTM) | |
|---|---|
| Revenue | JP¥4.57b |
| Cost of Revenue | JP¥1.50b |
| Gross Profit | JP¥3.07b |
| Other Expenses | JP¥2.25b |
| Earnings | JP¥812.00m |
Last Reported Earnings
Apr 30, 2024
Next Earnings Date
Sep 12, 2024
| Earnings per share (EPS) | 41.00 |
| Gross Margin | 67.13% |
| Net Profit Margin | 17.78% |
| Debt/Equity Ratio | 0% |
How did 4880 perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yieldn/a
Payout RatioDoes 4880 pay a reliable dividends?
See 4880 dividend history and benchmarks| CellSource dividend dates | |
|---|---|
| Ex Dividend Date | Oct 30 2024 |
| Dividend Pay Date | Jan 09 2025 |
| Days until Ex dividend | 68 days |
| Days until Dividend pay date | 139 days |
Does 4880 pay a reliable dividends?
See 4880 dividend history and benchmarks